Graham BS - Search Results

1

TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Johnson TR, Rao S, Seder RA, Chen M, Graham BS. Johnson TR, et al. Among authors: graham bs. Vaccine. 2009 May 18;27(23):3045-52. doi: 10.1016/j.vaccine.2009.03.026. Epub 2009 Apr 3. Vaccine. 2009. PMID: 19428918 Free PMC article.

2

Construction and characterization of recombinant vaccinia viruses co-expressing a respiratory syncytial virus protein and a cytokine.

Johnson TR, Fischer JE, Graham BS. Johnson TR, et al. Among authors: graham bs. J Gen Virol. 2001 Sep;82(Pt 9):2107-2116. doi: 10.1099/0022-1317-82-9-2107. J Gen Virol. 2001. PMID: 11514719

3

The role of IFN in respiratory syncytial virus pathogenesis.

Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, Graham BS. Durbin JE, et al. Among authors: graham bs. J Immunol. 2002 Mar 15;168(6):2944-52. doi: 10.4049/jimmunol.168.6.2944. J Immunol. 2002. PMID: 11884466

4

NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus.

Johnson TR, Hong S, Van Kaer L, Koezuka Y, Graham BS. Johnson TR, et al. Among authors: graham bs. J Virol. 2002 May;76(9):4294-303. doi: 10.1128/jvi.76.9.4294-4303.2002. J Virol. 2002. PMID: 11932395 Free PMC article.

5

Respiratory syncytial virus immunobiology and pathogenesis.

Graham BS, Rutigliano JA, Johnson TR. Graham BS, et al. Virology. 2002 May 25;297(1):1-7. doi: 10.1006/viro.2002.1431. Virology. 2002. PMID: 12083830 Free article. Review. No abstract available.

6

Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways.

Lee CG, Homer RJ, Cohn L, Link H, Jung S, Craft JE, Graham BS, Johnson TR, Elias JA. Lee CG, et al. Among authors: graham bs. J Biol Chem. 2002 Sep 20;277(38):35466-74. doi: 10.1074/jbc.M206395200. Epub 2002 Jul 9. J Biol Chem. 2002. PMID: 12107190 Free article.

7

IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge.

Johnson TR, Parker RA, Johnson JE, Graham BS. Johnson TR, et al. Among authors: graham bs. J Immunol. 2003 Feb 15;170(4):2037-45. doi: 10.4049/jimmunol.170.4.2037. J Immunol. 2003. PMID: 12574374

8

Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.

Johnson TR, Graham BS. Johnson TR, et al. Among authors: graham bs. Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2. Pediatr Infect Dis J. 2004. PMID: 14730270 Review.

9

Treatment with anti-LFA-1 delays the CD8+ cytotoxic-T-lymphocyte response and viral clearance in mice with primary respiratory syncytial virus infection.

Rutigliano JA, Johnson TR, Hollinger TN, Fischer JE, Aung S, Graham BS. Rutigliano JA, et al. Among authors: graham bs. J Virol. 2004 Mar;78(6):3014-23. doi: 10.1128/jvi.78.6.3014-3023.2004. J Virol. 2004. PMID: 14990720 Free PMC article.

10

Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Johnson TR, Teng MN, Collins PL, Graham BS. Johnson TR, et al. Among authors: graham bs. J Virol. 2004 Jun;78(11):6024-32. doi: 10.1128/JVI.78.11.6024-6032.2004. J Virol. 2004. PMID: 15141000 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

587 results

Search Page

Filters